Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Active Biotech

- PMLiVE

Teva to use cloud-based CRM for sales force

Picks Veeva’s system to streamline operations

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

- PMLiVE

Teva launches first generic of GSK’s Lovaza in US

Will have six months of marketing exclusivity for copy of cardiovascular drug

- PMLiVE

Teva backs UK’s dementia drive with $21m investment

Pharma company will support National Institute for Health Research

Teva Pharma logo

Teva launches first inhaled antipsychotic in US

Adasuve available for the treatment of agitation associated with schizophrenia or bipolar disorder

- PMLiVE

Teva’s Symbicort generic backed for EU approval

AstraZeneca braces for competition to COPD drug

- PMLiVE

Teva faces US marketing investigation

Department of Justice to probe promotion tactics for Copaxone and Azilect

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

- PMLiVE

Teva names Vigodman CEO and makes bid for NuPathe

Israeli pharma company confirms Jeremy Levin’s replacement

- PMLiVE

Key Teva shareholder backs Vigodman as next CEO

Board director tipped to replace Jeremy Levin at Israeli pharma firm

- PMLiVE

Teva’s vice chair steps down

Amir Elstein to take over from Moshe Many

- PMLiVE

Teva expects big things from improved drug programme

Aims to market enhanced versions of existing medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links